Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.
Chabon JJ, et al. Among authors: piotrowska z.
Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513.
Nat Commun. 2016.
PMID: 27841271
Free PMC article.
No abstract available.